Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Denali Therapeutics Inc (DNLI)

Denali Therapeutics Inc (DNLI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Denali Therapeutics Inc 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 USA

www.denalitherapeutics.com Employees: 422 P: 650-866-8547

Sector:

Medical

Description:

Denali Therapeutics, a biopharmaceutical company, is developing a wide and innovative portfolio of targeted therapeutic candidates, which are engineered to cross the blood-brain barrier for neurodegenerative diseases. It has 5 clinical-stage programs, a leucine-rich repeat kinase 2 inhibitor program partnered with Biogen to address Parkinson's disease, an eukaryotic translation initiation factor 2B activator program to address diseases such as amyotrophic lateral sclerosis and frontotemporal dementia (FTD), the ETV:IDS program, which utilizes the company's enzyme transport vehicle technology, and is designed to restore iduronate 2-sulfatase and reduce glycosaminoglycans, in patients with mucopolysaccharidosis II, and two separate receptor interacting serine/threonine protein kinase 1 inhibitor programs, both partnered with Sanofi. It also has a collaboration and option agreement with Takeda Pharmaceutical Co. Ltd. Takeda has exercised its option to jointly develop and commercialize DNL593 with the company.

Key Statistics

Overview:

Market Capitalization, $K 2,906,841
Enterprise Value, $K 2,731,881
Shares Outstanding, K 146,662
Float, K 128,329
% Float 87.50%
Short Interest, K 14,859
Short Float 10.13%
Days to Cover 9.68
Short Volume Ratio 0.56
% of Insider Shareholders 12.50%
% of Institutional Shareholders 92.92%

Financials:

Annual Sales, $ 0 K
Annual Net Income, $ -422,770 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -126,900 K
EBIT, $ -547,820 K
EBITDA, $ -575,140 K

Growth:

1-Year Return -4.32%
3-Year Return -35.48%
5-Year Return -69.84%
5-Year Revenue Growth -100.00%
5-Year Earnings Growth -24.15%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.74 on 11/06/25
Next Earnings Date 02/26/26 [--]
Earnings Per Share ttm -2.91
EPS Growth vs. Prev Qtr -2.78%
EPS Growth vs. Prev Year -17.46%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

DNLI Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -46.33%
Return-on-Assets % -40.99%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 3.29
Book Value/Share 6.33
Interest Coverage -3.65
60-Month Beta 1.02
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar